Matteo S. Carlino
0000-0002-7861-4104
Publication & Citation Trends
Publications
0 total
GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma
Cited by 0
Semantic Scholar
Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma OA
Cited by 0
Semantic Scholar
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study
Cited by 0
Semantic Scholar
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.
Cited by 6
Semantic Scholar
Distinct effect of neoadjuvant PD1 alone, PD1+IPI, and PD1+lenvatinib in the peripheral immune profile of melanoma patients (pts) and correlation with pathological (path) response.
Cited by 0
Semantic Scholar
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma.
Cited by 0
Semantic Scholar
Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma OA
Cited by 0
Semantic Scholar
A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
Cited by 4
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(393)
Melanoma and MAPK Pathways
(251)
CAR-T cell therapy research
(220)
Immunotherapy and Immune Responses
(155)
Cutaneous Melanoma Detection and Management
(145)
Affiliations
Université Paris-Sud
University of Technology Sydney
Camden and Campbelltown Hospitals
The University of Sydney
Mater Health Services